Signaling news
Here we present recent news items specially selected from Nature, Nature Medicine and Nature Biotechnology.
November 2002
2002:
December |
November |
October |
Other years: 2003 | 2004 | 2005 | 2006 | 2007 | 2008
News
Japan ponders steps to probe data errors
Where does the border lie between simple error and scientific misconduct? That is the question in the face of the Japanese research community by the unsavoury means of an anonymous letter.
Nature (28 November 2002)
| Full Text |
Venter aims for maximum impact with minimal genome
Not for the first time, geneticist Craig Venter's latest wheeze has set US biology abuzz.
Nature (28 November 2002)
| Full Text |
Visa clampdown hits home at US universities
Tighter immigration rules are causing a broad increase in visa delays and refusals for students and postdoctoral fellows seeking entry to the United States
Nature (28 November 2002)
| Full Text |
Cambridge-MIT Institute probed
The collaborative Cambridge-MIT Institute (CMI) is now seeking new leadership, amid scant evidence of its results and recurring questions about why it was set up in the first place.
Nature (21 November 2002)
| Full Text |
Congress backs historic expansion of NSF
In a major boost for the physical sciences in the US, Congress has passed a bill that recommends doubling the budget of the National Science Foundation (NSF) over the next five years.
Nature (21 November 2002)
| Full Text |
Cancer researcher found guilty of negligence
A university investigation has found the lead author of a contentious German cancer study guilty of gross negligence, but has cleared his 14 co-authors of misconduct.
Nature (21 November 2002)
| Full Text |
Outcry greets US plan to test smallpox vaccine on children
Plans to test a smallpox vaccine on small children in the US have been slammed by critics.
Nature (14 November 2002)
| Full Text |
Tribe blasts 'exploitation' of blood samples
Amerindians on Vancouver Island are incensed to discover that their donated blood specimens have been used for research other than what was consented for.
Nature (14 November 2002)
| Full Text |
Conduct code mooted for bioweapons treaty
A code of conduct for scientists could help to stengthen the international Biological and Toxin Weapons Convention (BTWC) according to Britain's Royal Society.
Nature (14 November 2002)
| Full Text |
Academy slams Internet arts and sciences lookalike
Two week's ago Nature revealed that the self-styled European Academny of Sciences appear to have no high-brow status despite grandiose claims. Now, it seems, a similar academy has emerged across the Atlantic.
Nature (14 November 2002)
| Full Text |
Republican win sparks fears for science funds
Fears are growing that the Republican's dominance of both houses of Congress will spell trouble for the future budgets of key science agencies.
Nature (14 November 2002)
| Full Text |
Gene therapy: A tragic setback
With one French gene-therapy patient having developed a form of cancer, a frantic detective effort is under way to determine what went wrong — and to assess the risks faced by others.
Nature (14 November 2002)
| Full Text |
Gene centre chips in with better route to microarrays
A new set of human DNA clones made available by the German Genome Resource Centre (RZPD) means than it will be easier for biologists to make their own DNA microarrays.
Nature (7 November 2002)
| Full Text |
Leukemia case triggers tighter gene-therapy controls
A hastily convened advisory committee to the US Food and Drug Adminstration (FDA) ruled last month that gene-therapy trials should now continue, but with increased monitoring for adverse events in patients.
Nature Medicine (November 2002)
| Full Text |
McClellan nominated to head FDA
In a choice that may satisfy a diverse array of competing interests, the Bush administration has finally nominated a director for the US Food and Drug Administration (FDA).
Nature Medicine (November 2002)
| Full Text |
More rare disease money
Thanks to two new companion bills passed by the US House of Congress last month, funding for the development of drugs and treatments for rare, or "orphan," disease is set to rise.
Nature Medicine (November 2002)
| Full Text |
Genome scientists' paths diverge
The two men who spearheaded the human genome sequencing effort have taken different paths in the aftermath of the project.
Nature Medicine (November 2002)
| Full Text |
FDA appointee faces angry, demoralized staff
If the Senate confirms the appointment of Mark McClellan as commissioner to the US FDA, as is expected, McClellan could confront serious tensions in dealing with the FDA Center for Biologics.
Nature Biotechnology (November 2002)
| Full Text |
Angiogenesis inhibitors suffer new setback
Genentech has announced that its Avastin monoclonal antibody targeting vascular endothelial growth factor (VEGF) failed a phase 3 clinical trial in metastatic breast cancer.
Nature Biotechnology (November 2002)
| Full Text |
US panel advises resumption of gene trials
Officials of the US FDA seem likely to release several ongoing gene-transfer experiments on patients with severe combined immunodeficienc syndrome (SCID) in the US from a "clinical hold".
Nature Biotechnology (November 2002)
| Full Text |
News in brief
US Congress streamlines PTO
| Amylin, Lilly in diabetes deal
| Kosan strikes cancer deal
| Nobel winners boost biotech
| California passes groundbreaking ES cell law
| Slump forces funding cut for Howard Hughes
News Features
Reproductive immunology: Immunity's pregnant pause
If we can understand why a woman's body does not reject her fetus, it could help us to treat infertility and prevent problems in pregnancy.
Nature (21 November 2002)
| Full Text |
|
